Roche pharma CEO Anderson talks up Vabysmo’s 'very strong launch' plans as Eylea battle looms

The FDA only recently approved Vabysmo, at the end of January, but Roche is already hyping up its launch, as it hopes to go toe-to-toe against ophthalmology powerhouse Eylea from Regeneron and Bayer.

Talking to investors and analysts after announcing its full-year results this week, Roche’s pharma chief Bill Anderson said “just digging through my text messages,” he found a text from a physician involved in treating “a lot of patients.”